WASHINGTON (UNITED STATES) - US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough."
The news sent shares in Moderna soaring 145 percent to $154 while Merck's stock was up more than 12 percent to $152.